Coordination Chemistry Reviews, Journal Year: 2023, Volume and Issue: 500, P. 215532 - 215532
Published: Nov. 10, 2023
Language: Английский
Advanced Materials, Journal Year: 2023, Volume and Issue: 36(3)
Published: Nov. 16, 2023
Lung cancer is the second most prevalent and leading cause of cancer-related death worldwide. Surgery, chemotherapy, molecular targeted therapy, immunotherapy, radiotherapy are currently available as treatment methods. However, drug resistance a significant factor in failure lung treatments. Novel therapeutics have been exploited to address complicated mechanisms advancement nanomedicine extremely promising terms overcoming resistance. Nanomedicine equipped with multifunctional tunable physiochemical properties alignment tumor genetic profiles can achieve precise, safe, effective while minimizing or eradicating cancer. Here, this work reviews discovered for radiotherapy, outlines novel strategies development against This focuses on engineering design, customized delivery, current challenges, clinical translation application resistant
Language: Английский
Citations
36
Science Bulletin, Journal Year: 2023, Volume and Issue: 68(10), P. 1069 - 1085
Published: April 27, 2023
Language: Английский
Citations
34
ACS Nano, Journal Year: 2023, Volume and Issue: 17(11), P. 10792 - 10805
Published: June 2, 2023
Natural melanin nanoparticles (MNPs) have demonstrated a potential for eliciting antitumor immune responses through inducing immunogenic cell death (ICD); however, the tumor microenvironment (TME) has been shown to inhibit T cell-mediated immunity. To address this challenge, we designed TME-responsive biodegradable melanin/MnOx nanohybrids via biomineralization process. Under near-infrared (NIR) light irradiation, photothermal property of triggers ICD and release tumor-associated antigens (TAAs), while Mn2+ TAAs induce dendritic (DC) maturation provoke responses. Furthermore, immunoregulatory properties themselves are exploited reshape immunosuppressive TME downregulate PD-L1 alleviation hypoxic acidic TME. Although MNPs demonstrate higher killing efficiency than in vitro due their superior effect, exhibit significantly enhanced antimetastatic effects vivo, benefiting from ability reverse immunosuppression DC maturation. Transcriptomics analysis confirmed successful activation This work presents promising approach immunomodulation-enhanced cancer therapy intrinsic nanohybrids.
Language: Английский
Citations
30
Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14
Published: Jan. 17, 2023
The tumor microenvironment (TME) is the surrounding environment, which critical for development and progression. TME also involved in clinical intervention treatment outcomes. Modulation of useful improving therapy strategies. PD-L1 protein on cells interacts with PD-1 T cells, contributing to cell dysfunction exhaustion, blockage immune response. Evidence has demonstrated that expression PD-1/PD-L1 associated response anti-PD-1/PD-L1 cancer patients. It important discuss regulatory machinery how finely regulated cells. In recent years, studies have was governed by various E3 ubiquitin ligases TME, resistance human cancers. this review, we will role molecular mechanisms ligases-mediated regulation TME. Moreover, describe ligases-involved alters efficacy. Altogether, targeting control levels could be a potential strategy potentiate immunotherapeutic effects
Language: Английский
Citations
27
Cancer Letters, Journal Year: 2023, Volume and Issue: 560, P. 216128 - 216128
Published: March 16, 2023
Language: Английский
Citations
25
MedComm, Journal Year: 2023, Volume and Issue: 4(3)
Published: May 29, 2023
Proteolysis targeting chimera (PROTAC) technology has become a powerful strategy in drug discovery, especially for undruggable targets/proteins. A typical PROTAC degrader consists of three components: small molecule that binds to target protein, an E3 ligase ligand (consisting and its recruiter), chemical linker hooks first two components together. In the past 20 years, we have witnessed advancement multiple degraders into clinical trials anticancer therapies. However, one major challenges is only very limited number recruiters are currently available as targeted protein degradation (TPD), although human genome encodes more than 600 ligases. Thus, there urgent need identify additional effective TPD applications. this review, summarized existing RING-type ubiquitin their act ligands application discovery. We believe review could serve reference future development efficient cancer discovery development.
Language: Английский
Citations
25
Advanced Materials, Journal Year: 2024, Volume and Issue: 36(38)
Published: June 20, 2024
Abstract While proteolysis‐targeting chimeras (PROTACs) hold great potential for persistently reprogramming the immunosuppressive tumor microenvironment via targeted protein degradation, precisely activating them in tissues and preventing uncontrolled proteolysis at off‐target sites remain challenging. Herein, a light‐triggered PROTAC nanoassembly (LPN) photodynamic indoleamine 2,3‐dioxygenase (IDO) is reported. The LPN derived from self‐assembly of prodrug conjugates, which comprise PROTAC, cathepsin B‐specific cleavable peptide linker, photosensitizer, without any additional carrier materials. In colon models, intravenously injected LPNs initially silence activity PROTACs accumulate significantly due to an enhanced permeability retention effect. Subsequently, cancer biomarker B begins trigger release active through enzymatic cleavage linkers. Upon light irradiation, cells undergo immunogenic cell death induced by therapy promote activation effector T cells, while continuous IDO degradation simultaneously blocks tryptophan metabolite‐regulated regulatory‐T‐cell‐mediated immunosuppression. Such LPN‐mediated combinatorial effectively inhibits growth, metastasis, recurrence. Collectively, this study presents promising nanomedicine, designed synergize with other immunotherapeutic modalities, more effective safer immunotherapy.
Language: Английский
Citations
16
Coordination Chemistry Reviews, Journal Year: 2024, Volume and Issue: 510, P. 215863 - 215863
Published: April 5, 2024
Language: Английский
Citations
15
Cancer Letters, Journal Year: 2024, Volume and Issue: 588, P. 216758 - 216758
Published: Feb. 22, 2024
Language: Английский
Citations
14
Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)
Published: Oct. 18, 2024
PROteolysis TArgeting Chimeras (PROTACs) have been considered the next blockbuster therapies. However, due to their inherent limitations, efficacy of PROTACs is frequently impaired by limited tissue penetration and particularly insufficient cellular internalization into action sites. Herein, based on ultra-pH-sensitive enzyme-sensitive nanotechnology, a type polymer PROTAC conjugated pH/cathepsin B sequential responsive nanoparticles (PSRNs) are deliberately designed, following construction for Cyclin-dependent kinase 4 6 (CDK4/6). Colorectal cancer (CRC) which hardly responds many treatments even immune checkpoint blockades was selected as tumor model in this study. As result, PSRNs were found maintain nanostructure (40 nm) circulation efficiently accumulated tumors via enhanced permeation retention effect. Then, they dissociated unimers (<10 response an acidic microenvironment, facilitating internalization. Eventually, CDK4/6 degrading released intracellularly cleavage cathepsin B. Importantly, led degradation target protein vitro vivo. The also augmented blockades, through upregulation programmed cell death-ligand 1 (PD-L1) expression cells suppression regulatory T proliferation microenvironment. By combination with α-PD-1, anti-tumor outcome well achieved CT26 model. Overall, our study verifies significance precise intracellular delivery introduces promising therapeutic strategy targeted treatment CRC.
Language: Английский
Citations
12